RT Journal Article
SR Electronic
T1 Taste alteration in COVID-19: a rapid review with data synthesis reveals significant geographical differences
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.09.11.20192831
DO 10.1101/2020.09.11.20192831
A1 Cirillo, Nicola
YR 2020
UL http://medrxiv.org/content/early/2020/09/13/2020.09.11.20192831.abstract
AB To facilitate a timely understanding of the differences in the prevalence of gustatory disturbances (GD) in individuals infected with SARS-CoV-2, we undertook a rapid systematic review of articles published in the repository of the National Library of Medicine (MEDLINE/PubMed) and medRxiv from their inception until September 3, 2020. The minimum requirements for completing a restricted systematic review were met. Of the 431 articles retrieved, 61 eligible studies (28,374 confirmed COVID-19 cases) from 20 countries were included in the analysis. The results show strong significant differences in the overall reported prevalence of GD between East Asia [13%, 95% CI 0.14-26.06%], Middle East [38.83%, 95% CI 27.47-50.19%], Europe [57.18%, 95% CI 52.35-62.01%], and The Americas [66.78%, 95% CI 54.77-78.79%]. There were no trends showing differences of GD prevalence in the available literature between February and August, 2020. These data show that there is a distinct geographical distribution of GD in COVID-19 patients and this may explain the differences of diagnostic criteria for COVID-19 case definition.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo specific fundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Not applicableAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesFull raw data available upon request